Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | XBP1 | P17861 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | PKM | P14618 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16178655 | 0.78 | MAPT (0.70) | MAPTKDM4EXBP1MAPK1ALDH1A1 | |
| SCHEMBL21799208 | 0.78 | MAPT (0.59) | MAPTKDM4EXBP1MAPK1ALDH1A1 | |
| SCHEMBL16188022 | 0.77 | KDM4E (0.58) | MAPTKDM4EXBP1MAPK1ALDH1A1 | |
| SCHEMBL12245305 | 0.71 | MAPT (0.50) | MAPTKDM4EXBP1MAPK1ALDH1A1 | |
| SCHEMBL10205946 | 0.70 | ALDH1A1 (0.69) | MAPTKDM4EXBP1MAPK1ALDH1A1 | |
| SCHEMBL5010875 | 0.70 | MAPK1 (0.59) | MAPTKDM4EXBP1MAPK1ALDH1A1 | |
| SCHEMBL11310071 | 0.69 | MAPT (0.52) | MAPTKDM4EXBP1MAPK1ALDH1A1 | |
| SCHEMBL12770167 | 0.67 | MYC (0.46) | MAPTKDM4EXBP1MAPK1ALDH1A1 | |
| SCHEMBL21799211 | 0.67 | MAPT (0.45) | MAPTKDM4EXBP1MAPK1ALDH1A1 | |
| SCHEMBL10029971 | 0.67 | ALDH1A1 (0.50) | MAPTKDM4EALDH1A1POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701702-B2 | Metathesis catalysts and methods thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160229877-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | NATIONAL SCIENCE FOUNDATION | 2016-08-11 | — | — | US | disclosed |
| US-9206211-B2 | Metathesis catalysts and methods thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-12-08 | — | — | US | disclosed |
| US-20140316088-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229877-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | CYP51A1, SQLE, MOGAT2 | MAPT 3449/4885KDM4E 2305/4885XBP1 1788/4885 |
| US-20140316088-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | CYP51A1, SQLE, MOGAT2 | MAPT 3449/4885KDM4E 2305/4885XBP1 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.